ArticleACS sensors2024
Fluorescent Chemosensors in the Creation of a Commercially Available Continuous Glucose Monitor.
Article in ACS sensors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Review
- Materials and System Design for Self-Decision Bioelectronic Systems.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Advancing the Development of Subcutaneous Glucose Biosensors: Cargo-Carrying Adhesive Biosensor Systems (CABs).Macromolecular bioscience · 2026Article
- Band-Pass Raman Spectroscopy Unlocks Compact Point-of-Care Noninvasive Continuous Glucose Monitoring.Analytical chemistry · 2025Article
- A Scoring Function for Monolayer-Protected Gold Nanoparticles Capable of Recognizing Small Organic Molecules in Solution.Journal of chemical theory and computation · 2025Article
- Enzyme-Based Solid-Phase Electrochemiluminescence Sensors with Stable, Anchored Emitters for Sensitive Glucose Detection.Biosensors · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fully automated insulin delivery (i.e., an artificial pancreas) would revolutionize diabetes disease management, minimize negative secondary disease outcomes, and simultaneously reduce health care costs and system burdens. Continuous glucose monitoring (CGM) is an essential aspect of the artificial pancreas. Abiotic fluorescent chemosensors play a key role in generating long-lived CGM sensors for this purpose. In this Perspective, we detail our initial discoveries of chemosensors for saccharides, as well as the development and advancement of bis((
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.